Webinar Registration: Relentless Innovation of Multispecific Design
Advancing Differentiated Bispecific Antibodies in Autoimmune Disease
How Cantai and Alloy designed and advanced high-performance bispecifics by engineering against known failure modes from day one
Designing Bispecifics That Hold Up in the Real World
How Alloy’s integrated model helped Cantai move faster and design with greater precision
Alloy Therapeutics and Institute for Protein Innovation Announce Strategic Collaboration to Advance Next-Generation Antibody Discovery
Partnership combines world-class protein engineering with scalable drug development to accelerate innovation Boston — May 5, 2026 — Alloy Therapeutics, a leading biotechnology ecosystem company, today announced a strategic collaboration with the Institute for Protein Innovation (IPI), a nonprofit leader in protein engineering and in vitro discovery. Together, the organizations will create bespoke VHH (nanobody) […]
On-demand Webinar: From Data to Decisions in Antibody Discovery – Integrating AI/ML
Download our webinar on Data to Decisions in Antibody Discovery – Integrating AI/ML. Watch now Webinar Overview: In this webinar, Alloy will share practical, production-grade AI/ML workflows for candidate selection, developability triage, and optimization. We’ll cover what works today, what doesn’t, and how integrated data infrastructure and high-throughput make-test loops turn models into compounding advantage. […]
Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
BOSTON — March 17, 2026 — Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and effective antibodies against targets that are difficult to address with current technologies. As part of […]
AI/ML in Antibody Discovery: What Works, What Doesn’t, What’s Next
Traditional antibody discovery is a war of attrition: screen thousands of candidates, fail late, and repeat. AI/ML changes that calculus by shifting failures from late and expensive to early and cheap. The result is fewer wet-lab cycles and a higher probability that the molecules you carry forward actually behave like drugs, while at the same time integrating learnings from failures at every stage.
From Data to Decisions in Antibody Discovery: Integrating AI/ML
WEBINAR Register for our upcoming webinar on integrating AI/ML workflows to drive smarter antibody selection, developability triage, and lead optimization. Tue, Mar. 31 | 11:00 AM EST Register Now Webinar Overview: AI/ML is reshaping antibody discovery, not by replacing the lab, but by making every wet-lab cycle smarter. In this webinar, Alloy will share practical, […]
Alloy Accelerates Mediar Timeline to the Clinic for Complex Fibrosis Targets
BOSTON – February 3, 2026 – Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced the successful completion of an antibody discovery collaboration with Mediar Therapeutics. Leveraging Alloy’s ATX-Gx™ human transgenic mouse platform, advanced genetic immunization strategies, and AI/ML-enabled discovery workflows, Alloy delivered a series […]
Accelerated Antibody Discovery for Complex Fibrosis Targets
Accelerating Antibody Discovery for Challenging Fibrosis Targets Download Case Study Contact Us Advancing a first-in-class fibrosis program against complex biology This case study highlights how Alloy’s antibody discovery platforms and execution model enabled Mediar Therapeutics to move a complex fibrosis program forward with speed and confidence, despite biological and technical barriers that stalled conventional discovery […]